You need significant clinical performance, and the significance is not enough. LL has to show it can be better than the leading NASH development candidates. A BP won't put hundreds of millions on the table for an inferior candidate that won't compete well with the advanced candidates.
Cytdodyn can easily get to a position where if may have some significance but not enough Ph2 efficacy to compete. The cost and time for a large Ph3 maybe too much for an underfunded biotech like Cytodyn. And without having compelling clinical data (which so far is where they are) they are stuck with a relatively worthless asset that is not worth spending more cash on.
Market Data 
Markets 
AI
